The regulation of EKI-785 to the growth of U937 cell line.
- Author:
Xiang-fei YUAN
1
;
Shi-hong LU
;
Yi FENG
;
Na LIU
;
Xin SONG
;
Min LU
Author Information
- Publication Type:Journal Article
- MeSH: Apoptosis; drug effects; Blotting, Western; Cell Proliferation; drug effects; Female; Humans; Mitogen-Activated Protein Kinase Kinases; metabolism; Ovarian Neoplasms; genetics; metabolism; pathology; Phosphorylation; Proto-Oncogene Proteins c-akt; metabolism; Quinazolines; pharmacology; RNA, Messenger; biosynthesis; genetics; Receptor, Epidermal Growth Factor; biosynthesis; genetics; Receptor, ErbB-2; antagonists & inhibitors; biosynthesis; genetics; Receptor, ErbB-4; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; drug effects; U937 Cells
- From: Chinese Journal of Oncology 2006;28(11):810-814
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEThe aim of this study was to explore the expression of erbBs in U937, an acute monocyte leukemia cell line, and their impact on the growth of this cell line.
METHODSExpression of erbBs was detected by RT-PCR and expression of erbB2 at protein level by Western blot. After U937 cells was treated with EKI-785, an irreversible specific inhibitor of erbBs, the growth was assessed by MTT and growth curve, apoptosis was detected by Annexin V-FITC Apoptosis Detection Kit, and signal pathway was detected by Western blot.
RESULTSerbB2-4 were expressed in U937 cell line, but not erbB1. Especially, protein of erbB2 was expressed in this cell line. After treating with EKI-785, the growth of U937 cells was inhibited and early apoptosis was induced. Moreover, the Ras/MAPK and the PI3K/Akt signaling pathways were all blocked.
CONCLUSIONerbBs may play key roles in the development of some leukemia. Therefore, erbBs may become new targets of treatment to leukemia, and EKI-785 has a potency of clinic use to leukemia.
